[Pharmacology of Janus Kinase Inhibitors]

Overview

Journal Hautarzt

Specialty Dermatology

Date 2019 Nov 20

PMID 31740978

Citations 4

Authors

F Solimani

F J Hilke

K Ghoreschi

Affiliations

Soon will be listed here.

Abstract

Modern dermatotherapy is dominated by the development of various biologicals and small molecules. Janus kinase inhibitors (JAKi) form a novel class of small molecular synthetic compounds inhibiting the intracellular signal transduction of cytokine receptors. Cytokines are key mediators in the pathophysiology of numerous inflammatory skin diseases. Many cytokines use so-called type I and II cytokine receptors, which associate with the Janus kinases JAK1, JAK2, JAK3 or TYK2. JAKi are under clinical investigation for inflammatory skin disease, specifically in phase 3 trials for psoriasis or atopic dermatitis. Since JAKi are tested in oral as well as in topical formulations, they could become very popular in dermatotherapy. The mechanisms of JAKi, their selectivity, preliminary efficacy data, and their safety profile are discussed in this article.

Citing Articles

The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.

Maglie R, Solimani F, Didona D, Pipito C, Antiga E, Di Zenzo G Front Med (Lausanne). 2023; 10:1128154.

PMID: 36814775 PMC: 9939461. DOI: 10.3389/fmed.2023.1128154.

Therapeutic strategies for oral lichen planus: State of the art and new insights.

Didona D, Caposiena Caro R, Sequeira Santos A, Solimani F, Hertl M Front Med (Lausanne). 2022; 9:997190.

PMID: 36267615 PMC: 9578567. DOI: 10.3389/fmed.2022.997190.

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Fadlalmola H, Albadrani M, Elhusein A, Mohamedsalih W, Swamy V, Mamanao D Dermatol Res Pract. 2021; 2021:8382761.

PMID: 34257642 PMC: 8245258. DOI: 10.1155/2021/8382761.

Skin manifestations in spondyloarthritis.

Meier K, Schloegl A, Poddubnyy D, Ghoreschi K Ther Adv Musculoskelet Dis. 2020; 12:1759720X20975915.

PMID: 33343725 PMC: 7727049. DOI: 10.1177/1759720X20975915.

References

Ghoreschi K, Laurence A, OShea J . Janus kinases in immune cell signaling. Immunol Rev. 2009; 228(1):273-87. PMC: 2782696. DOI: 10.1111/j.1600-065X.2008.00754.x. View

Wolk R, Armstrong E, Hansen P, Thiers B, Lan S, Tallman A . Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol. 2017; 11(5):1243-1256. DOI: 10.1016/j.jacl.2017.06.012. View

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

Juczynska K, Wozniacka A, Waszczykowska E, Danilewicz M, Wagrowska-Danilewicz M, Wieczfinska J . Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis. Mediators Inflamm. 2017; 2017:6716419. PMC: 5674508. DOI: 10.1155/2017/6716419. View

Schmidt T, Solimani F, Pollmann R, Stein R, Schmidt A, Stulberg I . T1/T17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol. 2018; 142(2):669-672.e7. DOI: 10.1016/j.jaci.2018.02.044. View

Relke N, Gooderham M . The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. J Cutan Med Surg. 2019; 23(3):298-306. DOI: 10.1177/1203475419833609. View

Wrobleski S, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J . Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019; 62(20):8973-8995. DOI: 10.1021/acs.jmedchem.9b00444. View

Kreins A, Ciancanelli M, Okada S, Kong X, Ramirez-Alejo N, Kilic S . Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015; 212(10):1641-62. PMC: 4577846. DOI: 10.1084/jem.20140280. View

Dhingra N, Guttman-Yassky E . A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol. 2014; 134(8):2071-2074. PMC: 4101909. DOI: 10.1038/jid.2014.141. View

10.

Wallace D, Furie R, Tanaka Y, Kalunian K, Mosca M, Petri M . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018; 392(10143):222-231. DOI: 10.1016/S0140-6736(18)31363-1. View

11.

Amber K, Maglie R, Solimani F, Eming R, Hertl M . Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs. 2018; 78(15):1527-1548. DOI: 10.1007/s40265-018-0976-5. View

12.

Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S . Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015; 17:362. PMC: 4704538. DOI: 10.1186/s13075-015-0880-2. View

13.

Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P . Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018; 379(14):1313-1321. DOI: 10.1056/NEJMoa1806382. View

14.

Bissonnette R, Papp K, Poulin Y, Gooderham M, Raman M, Mallbris L . Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016; 175(5):902-911. DOI: 10.1111/bjd.14871. View

15.

FISCHER E, KREBS E . Relationship of structure to function of muscle phosphorylase. Fed Proc. 1966; 25(5):1511-20. View

16.

Ghoreschi K, Gadina M . Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2013; 23(1):7-11. PMC: 3877164. DOI: 10.1111/exd.12265. View

17.

Hotz C, Boniotto M, Guguin A, Surenaud M, Jean-Louis F, Tisserand P . Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. J Invest Dermatol. 2016; 136(9):1768-1780. DOI: 10.1016/j.jid.2016.04.036. View

18.

Okiyama N, Furumoto Y, Villarroel V, Linton J, Tsai W, Gutermuth J . Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2013; 134(4):992-1000. PMC: 3961527. DOI: 10.1038/jid.2013.476. View

19.

Welsch K, Holstein J, Laurence A, Ghoreschi K . Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017; 47(7):1096-1107. DOI: 10.1002/eji.201646680. View

20.

Yang C, Khanna T, Sallee B, Christiano A, Bordone L . Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther. 2018; 31(6):e12656. PMC: 6585740. DOI: 10.1111/dth.12656. View